- Presentations
- 4
- Markets
- 1
Arixtra is a brand of Fondaparinux marketed by Mylan Institutional, with 4 presentations listed and registered in United States. Each presentation below has its own page with packs, documents and availability for export supply from India.
- Active ingredient (INN)
- Fondaparinux
- Brand owner
- Mylan Institutional
- Registered in
- United States
- Strengths and forms
- 10 mg/0.8 mL injection, 2.5 mg/0.5 mL injection, 5 mg/0.4 mL injection, 7.5 mg/0.6 mL injection
All presentations
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Arixtra 10 mg/0.8 mL injectionSubcutaneous | Mylan Institutional | US FDA | Available on request |
| Arixtra 2.5 mg/0.5 mL injectionSubcutaneous | Mylan Institutional | US FDA | Available on request |
| Arixtra 5 mg/0.4 mL injectionSubcutaneous | Mylan Institutional | US FDA | Available on request |
| Arixtra 7.5 mg/0.6 mL injectionSubcutaneous | Mylan Institutional | US FDA | Available on request |
Brand names and trademarks belong to their owners and are used only to identify products.
Request Arixtra
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.